W. P. Tew, Ovarian cancer in the older woman, J. Geriatr. Oncol, vol.7, p.31, 2016.

A. Cowppli-bony, Z. Uhry, V. Guizard, B. Trétarre, A. M. Bouvier et al., Survie des personnes atteintes de cancer France metropolitaine 1989-2013 tumeurs solides. Revue d'Épidémiologie et de Santé Publique, vol.64, pp.201-202, 2016.

E. Fourcadier, B. Tretarre, C. Gras-aygon, F. Ecarnot, J. P. Daures et al., Under-treatment of elderly patients with ovarian cancer: A population based study, BMC Cancer, vol.15, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01264477

L. Tortorella, G. Vizzielli, D. Fusco, W. C. Cho, R. Bernabei et al., Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments, Aging Dis, vol.8, pp.677-684, 2017.

J. S. Taylor, W. He, R. Harrison, H. Zhao, C. C. Sun et al., Disparities in treatment and survival among elderly ovarian cancer patients, Gynecol. Oncol, vol.151, pp.269-274, 2018.

M. S. Schuurman, R. Kruitwagen, J. E. Portielje, E. M. Roes, V. Lemmens et al., Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis, Gynecol. Oncol, vol.149, pp.270-274, 2018.

P. Shenoy and A. Harugeri, Elderly patients' participation in clinical trials, Perspect. Clin. Res, vol.6, pp.184-189, 2015.

J. Giuliani and F. Drudi, Ovarian cancer in elderly patients: A difference in treatment based on age?, Arch. Gynecol. Obstet, vol.286, pp.1545-1548, 2012.

A. Kumar, C. L. Langstraat, S. R. Dejong, M. E. Mcgree, J. N. Bakkum-gamez et al., Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer, Gynecol. Oncol, vol.147, pp.104-109, 2017.

M. Charlson, T. P. Szatrowski, J. Peterson, and J. Gold, Validation of a combined comorbidity index, J. Clin. Epidemiol, vol.47, pp.1245-1251, 1994.

L. De-decker and . L'indice-de-co-morbidité-de-charlson, Annales de Gérontologie, vol.2, pp.159-160, 2009.

G. D. Aletti, E. L. Eisenhauer, A. Santillan, A. Axtell, G. Aletti et al., Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment, Gynecol. Oncol, vol.120, pp.23-28, 2011.

V. Lavoué, C. Huchon, C. Akladios, P. Alfonsi, N. Bakrin et al., Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa, Eur. J. Obstet. Gynecol. Reprod. Biol, vol.236, pp.214-223, 2019.

P. Harter, J. Sehouli, D. Lorusso, A. Reuss, I. Vergote et al., A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms, Engl. J. Med, vol.380, pp.822-832, 2019.

M. E. Charlson, P. Pompei, K. L. Ales, and C. R. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation, J. Chronic Dis, vol.40, pp.373-383, 1987.

A. Fagotti, G. Ferrandina, F. Fanfani, A. Ercoli, D. Lorusso et al., A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study, Ann. Surg. Oncol, vol.13, pp.1156-1161, 2006.

P. H. Sugarbaker and K. A. Jablonski, Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy, Ann. Surg, vol.221, pp.124-132, 1995.

G. D. Aletti, A. Santillan, E. L. Eisenhauer, J. Hu, G. Aletti et al., A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model, Gynecol. Oncol, vol.107, pp.99-106, 2007.

J. S. Berek, S. T. Kehoe, L. Kumar, and M. Friedlander, Cancer of the ovary, fallopian tube, and peritoneum, Int. J. Gynaecol. Obstet, vol.143, pp.59-78, 2018.

D. Dindo, N. Demartines, and P. A. Clavien, Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann. Surg, vol.240, pp.205-213, 2004.

A. Ferrero, L. Fuso, E. Tripodi, R. Tana, A. Daniele et al., Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index, Int. J. Gynecol. Cancer, vol.27, pp.1863-1871, 2017.

R. N. Eskander, J. Kauderer, K. S. Tewari, R. S. Mannel, R. E. Bristow et al., Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study, Gynecol. Oncol, vol.149, pp.525-530, 2018.

I. A. Burger, D. A. Goldman, H. A. Vargas, M. W. Kattan, C. Yu et al., Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer, Gynecol. Oncol, vol.138, pp.554-559, 2015.

D. S. Chi, P. T. Ramirez, J. B. Teitcher, S. Mironov, D. M. Sarasohn et al., Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less, J. Clin. Oncol, vol.25, pp.4946-4951, 2007.

I. Vergote, C. G. Tropé, F. Amant, G. B. Kristensen, T. Ehlen et al., Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N. Engl. J. Med, vol.363, pp.943-953, 2010.

A. Phillips, K. Singh, R. Pounds, S. Sundar, S. Kehoe et al., Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer, J. Obstet. Gynaecol, vol.37, pp.1070-1075, 2017.

G. Amadio, C. Marchetti, E. R. Villani, D. Fusco, F. Stollagli et al., ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): A case-control study of a real-life experience, J. Gynecol. Oncol, 2020.

F. Selle, N. Colombo, J. Korach, C. Mendiola, A. Cardona et al., Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (>/=70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study, Int. J. Gynecol. Cancer, vol.28, pp.729-737, 2018.

L. Rossi, M. Verrico, E. Zaccarelli, A. Papa, M. Colonna et al., Bevacizumab in ovarian cancer: A critical review of phase III studies, Oncotarget, vol.8, pp.12389-12405, 2017.

C. Falandry, A. M. Savoye, L. Stefani, F. Tinquaut, D. Lorusso et al., EWOC-1: A randomized trial to evaluate the feasability of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study, J. Clin. Oncol, vol.37, 2019.